SUMMARY The effect of a long-acting nitrate, isosorbide dinitrate (ID) 5 mg sublingually, on the lower oesophageal sphincter was tested in 24 patients with achalasia. The drug caused a reduction in LOS pressure in all cases. The mean LOS pressure fell from 46.3 ±2.7 mmHg to 15.3 +1 8 mmHg (P <0.01). The pressure began to drop after several minutes, reaching its lowest levels after 15 minutes. This measured manometric effect lasted for 60 minutes or more in 10 patients studied. The reported clinical effect lasted for two to three hours, permitting the ingestion of a meal. Twentythree patients were followed clinically for two to 19 months while receiving the drug three times daily before meals. Nineteen reported a marked to complete relief of dysphagia. Five of these patients had previous pneumatic dilatation, cardiomyotomy, or both, and had recurrence at time of study. Side-effects, mainly headache, were reported in eight patients. In six this was alleviated by substituting oral isosorbide dinitrate, 10 mg. Two patients became refractory to treatment after two to six months. The potential role of long-acting nitrates in the treatment of achalasia has yet to be established.
Present-day therapy for achalasia is symptomatic, aimed at reducing the lower oesophageal sphincter pressure (LOSP). Pneumatic dilatation and cardiomyotomy are both effective by causing mechanical damage to the sphincter. They carry a small but appreciable morbidity and even mortality. Because the dysphagia in achalasia is caused by a functional, not a mechanical, obstruction, it is logical to look for pharmacological means of reducing the raised LOSP.
Despite several trials involving anticholinergics and adrenergic blockers,1-7 there is at present no drug suitable for this purpose. Short-acting nitrates and nitrites were evaluated in the 1940s and 1950s5-l1 and discarded because of side-effects and brief duration of action.
In the present study long-acting nitrates were evaluated manometrically and clinically and found to be of value in the treatment of the disease. Methods PATIENTS Twenty-four patients with achalasia were studied.
*Address for correspondence and reprint requests: T Gilat, MD, Ichilov Hospital, Weizmann Street, Tel-Aviv, Israel. Received for publication 18 November 1980 Each had typical symptoms for more than one year. Radiographic studies, oesophagogastroscopy, and an oesophageal motility test were performed in each case and were diagnostic of achalasia. Their clinical and manometric data are given in Table 1 . Fifteen of the patients were females, nine males, and their ages ranged from 21 to 78 years. Eight had undergone previous therapy (pneumatic dilatation and/or cardiomyotomy) and were again symptomatic at the time of study.
All patients had dysphagia; 17 had regurgitation; nine had pulmonary symptoms; and 14 had a weight loss of over 5 kg. Dilatation of the oesophagus was assessed radiologically and endoscopically. As radiographic studies were performed at various institutions without a standardised technique, the dilatation was graded arbitrarily as mild (1 +), moderate (2+), or severe-'sigmoid' oesophagus (3+). Six patients had no dilatation of the oesophagus.
On manometric study all but two patients had an LOSP of 30 mmHg or more. None had complete relaxation of the sphincter during swallowing; 11 had incomplete relaxation; the others had no relaxation. The contractions in the body of the oesophagus were simultaneous in 22 patients (in five they were 312 At the end of each study the patients were given a sandwich to eat and were asked about dysphagia. Each patient was then given ID 5 mg sublingual tablets to be taken three times a day 15 minutes before meals. They were then invited for follow-up at one week, one month, and then every two to three months. At each visit they were questioned about their dysphagia. The results were graded as good (no dysphagia), moderate (marked improvement with occasional dysphagia), and poor (no significant improvement.)
The statistical significance of differences was tested by Student's 80- 
SIDE-EFFECTS
Seven patients complained of severe headache during sublingual ID treatment. Two of them were among the four without clinical relief; in the other five, the treatment was changed to 10 mg ID orally with a satisfactory result and with relief of the headache. Another patient developed syncope and was then treated with the oral preparation with good results. One young girl (no. 17) refused to take tablets continuously for social reasons and pneumatic dilatation was performed despite the good result of ID therapy for two months.
CORRELATIONS
The clinical response during ID therapy was correlated with several disease parameters. No definite correlation was found with duration of symptoms or oesophageal dilatation. There was a suggestion of a better clinical result in cases with higher LOS pressure (Table 4) . There was also a suggestion of a correlation between a high initial LOSP and the drop in pressure after ID (Fig. 4) . The correlation did not reach a level of statistical significance (r=0-78± 009).
In Table 5 the clinical result is correlated with the drop in LOS pressure. A higher drop in LOS pressure may be associated with a better clinical result. The data in both Tables 4 and 5 are not suitable for statistical analysis because of the small numbers involved. 
NITROGLYCERIN
In five patients with achalasia the effect of a shortacting nitrate (nitroglycerin 0.65 sublingually) was evaluated in a separate study. The results given in Table 6 show a significant and rapid drop in LOSP which was, however, of short duration.
Discussion
Several drugs have been used in an attempt to overcome the functional obstruction of the LOS in achalasia. Anticholinergics2-7 and adrenergic blockers1 act on the nervous elements in the oesophageal wall. Results obtained with anticholinergics were variable and the use of adrenergic blockers is fraught with side-effects. Both are not commonly used in the treatment of achalasia. Nitrites and nitrates are known to relax human smooth muscle of several systems, including the digestive tract and, in particular, the oesophagus.13-16 Short-acting nitrates and nitrites were evaluated in achalasia in the 1940s and 1950s by four groups of investigators.8-1' All four were radiographic and clinical studies without manometric confirmation. These radiographic studies demonstrated a relaxation of the cardia with passage of the barium column into the stomach after amyl or octyl nitrite inhalation or sublingual nitroglycerin. The duration of action, as determined clinically or by radiographs was short, four to 30 minutes, and was associated with sideeffects such as headaches and hypotension. We are not aware of additional studies and nitrates are not currently used in the treatment of achalasia.
We first measured manometrically the effect of short-acting nitrates on the LOS pressure in achalasia (Table 6 ) and having objectively demonstrated a decrease in pressure proceeded to evaluate a longer acting compound to obtain a prolonged clinical effect and minimise side-effects. We believe that other smooth muscle relaxants should also be evaluated in the treatment of this disease.
The results obtained with isosorbide dinitrate 5 mg sublingually are manometrically and clinically significant. The mean fall in LOS pressure was 66 %, similar to the approximately 70% after pneumatic dilatation." The duration of the measured fall in LOS pressure (30 to more than 90 minutes) and the clinical relief of dysphagia (up to two to three hours) after a single tablet are adequate for the ingestion of a regular meal. The duration of the clinical effect reported by our patients corresponds to the duration of the cardiovascular effect of ID as established by haemodynamic studies.18 One problem encountered with this treatment is the known loss of potency of nitrates with increasing shelf life.15 This may affect both the magnitude and duration of the clinical and manometric effect.
The proportion of satisfactory results (19/23) does not differ markedly from that reported with pneumatic dilation or cardiomyotomy.'920 Unlike the two other methods of treatment, no mortality or morbidity is involved. Side-effects were noted in a considerable proportion of patients (8/24). This is more than usually encountered by cardiologists. The side-effects themselves were not serious, mostly headaches, and could, in some cases, be alleviated by substituting oral ID or another oral nitrate.
We cannot yet evaluate the duration of the beneficial effect of ID or the proportion of clinical failure with time. The duration of follow-up (up to 19 months) is still too short for this purpose. It should be noted that recurrences also occur after pneumatic dilatationl9-2' and even cardiomyotomy.20-23 There were eight such patients in our series, and in five of these ID therapy was helpful.
To the best of our knowledge, this is the first report of its kind. The results have to be confirmed by other investigators, and more data have to be gathered before the eventual place of nitrates in the overall treatment of achalasia can be established. 
